Remedium Bio

Innovative Therapeutics fulfilling the potential of gene therapy

  • Stage Prototype Ready
  • Industry Biotechnology
  • Location Boston, MA, USA
  • Currency USD
  • Founded February 2020
  • Employees 4
  • Incorporation Type C-corp
  • Website remedium-bio.com

Company Summary

Remedium Bio is a biotechnology company developing technologies that overcome the hurdles preventing wider adoption of gene therapy, and access to its curative potential. Their next-generation dose-adjustable gene therapy platform, Prometheus™, has the potential to revolutionize gene therapy and recombinant protein delivery.

Team

  • Alex Goraltchouk
    Chief Operating Officer

    15+ years experience in biotech and gene therapy at companies ranging from start-up to Fortune 500 (Allergan, Biogen, Regeneron, Avedro / Glaukos, and Anika). Experience developing and launching blockbuster products including Enbrel and Humira biosimilars, Spinraza, Praluent, Kevzara, Cingal, among numerous others.

  • Frank Luppino
    President and CEO

    20+ years biotech and rheumatology experience, brought multiple blockbuster products to market including Monovisc, Orthovisc, Cingal, and Hyalofast (several of which are currently distributed by JNJ). Grew previous company as COO from a cap of $6M to $1B.

  • Alexey Seregin
    Vice President of R&D

    Dr. Seregin is a subject matter expert in gene therapy and virology with an extensive background leading R&D organizations at companies including Biogen, Takeda, Bioverativ, and Solid Biosciences.

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free